Funding Organization(s): National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID), National Science Foundation (NSF, United States), American Cancer Society, Department of Defense (DOD, United States), National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)
Primary Citation of Related Structures:   7LO7, 7LO8
PubMed Abstract: 
Membrane protein efflux pumps confer antibiotic resistance by extruding structurally distinct compounds and lowering their intracellular concentration. Yet, there are no clinically approved drugs to inhibit efflux pumps, which would potentiate the efficacy of existing antibiotics rendered ineffective by drug efflux. Here we identified synthetic antigen-binding fragments (Fabs) that inhibit the quinolone transporter NorA from methicillin-resistant Staphylococcus aureus (MRSA). Structures of two NorA-Fab complexes determined using cryo-electron microscopy reveal a Fab loop deeply inserted in the substrate-binding pocket of NorA. An arginine residue on this loop interacts with two neighboring aspartate and glutamate residues essential for NorA-mediated antibiotic resistance in MRSA. Peptide mimics of the Fab loop inhibit NorA with submicromolar potency and ablate MRSA growth in combination with the antibiotic norfloxacin. These findings establish a class of peptide inhibitors that block antibiotic efflux in MRSA by targeting indispensable residues in NorA without the need for membrane permeability.
Organizational Affiliation: 
Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY, USA.
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Department of Chemistry, New York University, New York, NY, USA.
Department of Microbiology, New York University School of Medicine, New York, NY, USA.
Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Department of Medicine, New York University School of Medicine, New York, NY, USA.
Cryo-Electron Microscopy Facility, New York University School of Medicine, New York, NY, USA.
Kobilka Institute of Innovative Drug Discovery, School of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen, China.
Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA. shohei.koide@nyulangone.org.
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA. shohei.koide@nyulangone.org.
Antimicrobial-Resistant Pathogens Program, New York University School of Medicine, New York, NY, USA.
Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY, USA. da-neng.wang@med.nyu.edu.
Department of Cell Biology, New York University School of Medicine, New York, NY, USA. da-neng.wang@med.nyu.edu.
Department of Chemistry, New York University, New York, NY, USA. traaseth@nyu.edu.